The clinical development of antibody–drug conjugates — lessons from leukaemia
- 23 March 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 18 (7), 418-433
- https://doi.org/10.1038/s41571-021-00484-2
Abstract
Advances in our understanding of cancer biology have enabled drug development to progress towards better targeted therapies that are both more effective and safer owing to their lack of off-target toxicities. In this regard, antibody–drug conjugates (ADCs), which have the potential to combine the selectivity of therapeutic antibodies with the cytotoxicity of highly toxic small molecules, are a rapidly developing drug class. The complex and unique structure of an ADC, composed of a monoclonal antibody conjugated to a potent cytotoxic payload via a chemical linker, is designed to selectively target a specific tumour antigen. The success of an ADC is highly dependent on the specific properties of its components, all of which have implications for the stability, cytotoxicity, pharmacokinetics and antitumour activity of the ADC. The development of therapeutic ADCs, including gemtuzumab ozogamicin and inotuzumab ozogamicin, provided great knowledge of the refinements needed for the optimization of such agents. In this Review, we describe the key components of ADC structure and function and focus on the clinical development and subsequent utilization of two leukaemia-directed ADCs — gemtuzumab ozogamicin and inotuzumab ozogamicin — as well as on the mechanisms of resistance and predictors of response to these two agents.Keywords
This publication has 138 references indexed in Scilit:
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With RituximabJournal of Clinical Oncology, 2013
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesmAbs, 2013
- P-glycoprotein Inhibition for Optimal Drug DeliveryDrug Target Insights, 2013
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding TrialTransplantation and Cellular Therapy, 2010
- Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapyCancer Science, 2010
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaThe New England Journal of Medicine, 2009
- A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow CytometryImmunological Investigations, 2006
- Structure of a Covalent DNA Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand CrosslinkingJournal of Medicinal Chemistry, 1994
- Detection of mycoplasma contamination in lymphoblastoid cell lines by monoclonal antibodiesHuman Immunology, 1984
- Immunoradioactive agent against cancer.BMJ, 1967